Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AM3101
- Development stage
- Phase 2
- Lead developer
- Amplicore
- Modality
- Peptides
- Administration
- Intraarticular
01
Overview
AM3101 is a regenerative therapeutic candidate developed by Amplicore for the treatment of acute meniscal tears. Originating from research at the University of Cincinnati, the drug is designed for local, minimally invasive delivery to promote tissue healing and regeneration following surgical repair of the meniscus. The program has received significant support from the U.S. Department of Defense (DoD), including a $2 million grant to fund a Phase 1/2b clinical trial, specifically addressing injuries that are common among military personnel. AM3101 represents a regenerative approach to musculoskeletal diseases, aiming to improve long-term outcomes for patients with acute joint injuries.
Beyond the preview
Go deeper on AM3101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AM3101.